Skip to main content

Table 1 Patient characteristics in both study groups and average dosages during run-in phase and treatment phase in both groups

From: Levo-α-acetylmethadol (LAAM) induced QTc-prolongation - results from a controlled clinical trial

Treatment Group Methadone (METH) LAAM
Total number (n) 22 31
Gender 12 F/10 M 11 F/20 M
Age (avg) 31.0 yrs 27.9 yrs
Average dosage during run-in period (METH in both groups) 72.0 ± 25.5 mg daily 73.5 ± 25.7 mg daily
Average dosage during treatment phase 69 ± 27.6 mg METH Mon & Wed Fri
   89.6 ± 32.4 mg LAAM 109.7 ± 39.5 mg LAAM
   equiv. to 68.9 ± 24.9 mg METH* equiv. to 68.6 ± 24.7 mg METH*
  1. *For better comparability, METH equivalents are shown in the LAAM groups assuming a factor of 1.3 (Monday & Wednesday) and 1.6 (Friday).